Pfizer, BioNTech End mRNA COVID-19 Biologic Trial Early
After failing to recruit enough eligible volunteers to generate enough data in the U.S. to meet U.S. Food and Drug Administration (FDA) post-marketing evidence requirements, Pfizer, Inc. and BioNTech SE have halted a large clinical trial of their updated mRNA COVID-19 biologic. The study targeted healthy adults 50 to 64 years of age but fell […]
Poland, Romania Resist Brussels Court Order to Pay $2.2 Billion to Pfizer
A court in Belgium has ordered Poland and Romania to proceed with paying €1.9 billion ($2.2 billion) for purchasing mRNA COVID-19 shots from Pfizer, Inc. and BioNTech SE in a case brought by Pfizer three years ago. The lawsuit and court judgement has intensified a broader legal dispute over mRNA COVID shot contracts signed by […]
Injured Former Chicago Baseball Prospect Sues Team and League Over COVID-19 Shot
Isaiah Carranza, a former Chicago White Sox minor and major league pitching prospect has filed a lawsuit asserting that the White Sox and Major League Baseball (MLB) coerced him into receiving a COVID-19 shot in 2021, an injection which caused adverse reactions severe enough to end his baseball career. The federal lawsuit, which was filed […]
Texas Attorney General Investigates Doctors Receiving Money Incentives to Vaccinate Children
Texas Attorney General Ken Paxton recently announced that his office has opened an investigation into financial incentives connected to doctors administering vaccines to children. Paxton said the probe will examine pediatricians, insurers, vaccine manufacturers, and other entities that may have engaged in deceptive or unlawful conduct by failing to disclose financial incentives tied to the […]
Changes in Eye Health Linked to mRNA COVID-19 Shots
A recent prospective study published in 2025 in Ophthalmic Epidemiology has identified measurable changes in the cornea of the eye following receipt of mRNA COVID-19 biological, raising new questions about potential effects on eye health. Researchers observed differences in corneal thickness and endothelial cell characteristics in healthy adults after two doses of Pfizer/BioNTech’s Comirnaty COVID […]
Novavax Signs Licensing Agreement With Pfizer for Vaccine Adjuvant Technology
Novavax, Inc. and Pfizer, Inc. have signed a licensing arrangement allowing Pfizer access to Novavax’s Matrix-M adjuvant technology to boost immune response to vaccines. The agreement will allow for use in vaccines targeting up to two infectious diseases.1 Novavax’s Matrix-M technology is an aluminum-free adjuvant designed to enhance the immune response in protein-based vaccines such […]